TY - JOUR
T1 - Specialized Donor Care Facility Model and Advances in Management of Thoracic Organ Donors
AU - Bery, Amit
AU - Marklin, Gary
AU - Itoh, Akinobu
AU - Kreisel, Daniel
AU - Takahashi, Tsuyoshi
AU - Meyers, Bryan
AU - Nava, Ruben
AU - Kozower, Benjamin
AU - Shepherd, Hailey
AU - Patterson, G. Alexander
AU - Puri, Varun
N1 - Funding Information:
Dr Varun Puri received grant support from the Mid-America Transplant Foundation (grant 1 I01 HX002475-01A2), Department of Veterans Affairs (Health Services Research Grant; 1 R01HL146856-01A1), and National Heart, Lung, and Blood Institute (Institute of Public Health, Center for Dissemination and Implementation grant 2019-01-PG). Dr Daniel Kreisel received grant support from the National Institutes of Health (grants 1P01AI116501, R01 HL094601, and R01HL151078), Veterans Administration Merit Review (grant 1I01BX002730), The Cystic Fibrosis Foundation , and The Foundation for Barnes-Jewish Hospital. Dr Daniel Kreisel has a pending patent entitled “Compositions and methods for detecting CCR2 receptors” (application number 15/611,577).
Funding Information:
Dr Varun Puri received grant support from the Mid-America Transplant Foundation (grant 1 I01 HX002475-01A2), Department of Veterans Affairs (Health Services Research Grant; 1 R01HL146856-01A1), and National Heart, Lung, and Blood Institute (Institute of Public Health, Center for Dissemination and Implementation grant 2019-01-PG). Dr Daniel Kreisel received grant support from the National Institutes of Health (grants 1P01AI116501, R01 HL094601, and R01HL151078), Veterans Administration Merit Review (grant 1I01BX002730), The Cystic Fibrosis Foundation, and The Foundation for Barnes-Jewish Hospital. Dr Daniel Kreisel has a pending patent entitled “Compositions and methods for detecting CCR2 receptors” (application number 15/611,577).
Publisher Copyright:
© 2022 The Society of Thoracic Surgeons
PY - 2022/6
Y1 - 2022/6
N2 - Background: Donor hearts and lungs are more susceptible to the inflammatory physiologic changes that occur after brain death. Prior investigations have shown that protocolized management of potential organ donors can rehabilitate donor organs that are initially deemed unacceptable. In this review we discuss advances in donor management models with particular attention to the specialized donor care facility model. In addition we review specific strategies to optimize donor thoracic organs and improve organ yield in thoracic transplantation. Methods: We performed a literature review by searching the PubMed database for medical subject heading terms associated with organ donor management models. We also communicated with our local organ procurement organization to gather published and unpublished information first-hand. Results: The specialized donor care facility model has been shown to improve the efficiency of organ donor management and procurement while reducing costs and minimizing travel and its associated risks. Lung protective ventilation, recruitment of atelectatic lung, and hormone therapy (eg, glucocorticoids and triiodothyronine/thyroxine) are associated with improved lung utilization rates. Stroke volume–based resuscitation is associated with improved heart utilization rates, whereas studies evaluating hormone therapy (eg, glucocorticoids and triiodothyronine/thyroxine) have shown variable results. Conclusions: Lack of high-quality prospective evidence results in conflicting practices across organ procurement organizations, and best practices remain controversial. Future studies should focus on prospective, randomized investigations to evaluate donor management strategies. The specialized donor care facility model fosters a collaborative environment that encourages academic inquiry and is an ideal setting for these investigations.
AB - Background: Donor hearts and lungs are more susceptible to the inflammatory physiologic changes that occur after brain death. Prior investigations have shown that protocolized management of potential organ donors can rehabilitate donor organs that are initially deemed unacceptable. In this review we discuss advances in donor management models with particular attention to the specialized donor care facility model. In addition we review specific strategies to optimize donor thoracic organs and improve organ yield in thoracic transplantation. Methods: We performed a literature review by searching the PubMed database for medical subject heading terms associated with organ donor management models. We also communicated with our local organ procurement organization to gather published and unpublished information first-hand. Results: The specialized donor care facility model has been shown to improve the efficiency of organ donor management and procurement while reducing costs and minimizing travel and its associated risks. Lung protective ventilation, recruitment of atelectatic lung, and hormone therapy (eg, glucocorticoids and triiodothyronine/thyroxine) are associated with improved lung utilization rates. Stroke volume–based resuscitation is associated with improved heart utilization rates, whereas studies evaluating hormone therapy (eg, glucocorticoids and triiodothyronine/thyroxine) have shown variable results. Conclusions: Lack of high-quality prospective evidence results in conflicting practices across organ procurement organizations, and best practices remain controversial. Future studies should focus on prospective, randomized investigations to evaluate donor management strategies. The specialized donor care facility model fosters a collaborative environment that encourages academic inquiry and is an ideal setting for these investigations.
UR - http://www.scopus.com/inward/record.url?scp=85113314643&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2020.12.026
DO - 10.1016/j.athoracsur.2020.12.026
M3 - Review article
C2 - 33421385
AN - SCOPUS:85113314643
SN - 0003-4975
VL - 113
SP - 1778
EP - 1786
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 6
ER -